Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
chemotherapy regimen
|
| gptkbp:administeredCycle |
every 2 weeks
|
| gptkbp:alternativeName |
Leucovorin, 5-FU, and irinotecan
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01XY07
|
| gptkbp:combines |
gptkb:bevacizumab
gptkb:cetuximab |
| gptkbp:firstDescribed |
1990s
|
| https://www.w3.org/2000/01/rdf-schema#label |
FOLFIRI
|
| gptkbp:includesDrug |
gptkb:irinotecan
gptkb:fluorouracil folinic acid |
| gptkbp:mechanismOfAction |
inhibits DNA synthesis
inhibits topoisomerase I |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
nausea
vomiting diarrhea fatigue hair loss neutropenia |
| gptkbp:usedAs |
first-line therapy
second-line therapy |
| gptkbp:usedFor |
colorectal cancer
metastatic colorectal cancer advanced colorectal cancer |
| gptkbp:bfsParent |
gptkb:Cyramza
|
| gptkbp:bfsLayer |
8
|